Your Health, We Care
Dacomitinib is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
from FDA，2020.12
The first-line treatment for metastatic non-small cell lung cancer with epiderma···【more】
Release date：2026-01-05Recommended：16
LuciusVersionofDacomitinib:DosageandAdministration,Indications,PrecautionsIndica···【more】
Release date：2025-12-17Recommended：66
